Is Your Paper Ready for Frontiers in Microbiology? Picking the Right Section

This is the most misunderstood aspect of submitting to any Frontiers journal. When you submit to Frontiers in Microbiology, you aren't just tagging your paper with a topic label. You're choosing which editorial team handles it, which reviewers evaluate it, and what intellectual framework gets applied to your work.

The sections include Antimicrobials, Resistance and Chemotherapy; Evolutionary and Genomic Microbiology; Food Microbiology; Infectious Agents and Disease; Microbiomes; Microbiotechnology; Systems Microbiology; Virology; Fungi and Their Interactions; Antimicrobial Immunity; Aquatic Microbiology; and many more. Each one has a chief editor, associate editors, and a distinct reviewer network.

Here's why this matters more than most authors realize. A paper on antimicrobial resistance in wastewater bacteria could reasonably go to Antimicrobials, Resistance and Chemotherapy; Aquatic Microbiology; or even Microbiomes depending on the framing. But the reviewers in each section bring different expectations. The antimicrobials section editors want to see MIC data, resistance gene characterization, and clinical relevance. The aquatic microbiology editors want environmental context, sampling methodology, and ecological interpretation. Same dataset, different evaluation lenses.

The practical test: Search your target section's recent publications. Can you find 5-10 papers from the past two years that your manuscript would cite or that would naturally cite yours? If yes, you're in the right place. If you're scrolling through pages of results without finding anything related, you've got the wrong section.

I've seen papers bounce through review because an author studying Candida biofilm formation submitted to a general microbiology section instead of Fungi and Their Interactions. The reviewers they got were bacteriologists who spent three rounds asking for experiments that made sense for bacterial biofilms but were irrelevant for fungal systems. That's not the reviewers' fault. It's a section selection problem.

Frontiers' review model is genuinely different from what you'll encounter at Applied and Environmental Microbiology or the FEMS journals, and it's worth understanding the mechanics.

After a handling editor (associate editor in Frontiers terminology) accepts your paper for review, they assign it to a review editor. That review editor recruits 2-3 reviewers and then does something unusual: they actively coordinate the review process rather than just collecting reports. If Reviewer 1 wants additional controls and Reviewer 2 thinks the controls you have are fine, the review editor is supposed to resolve that tension before sending you a contradictory set of demands.

In theory, this is great. Anyone who's received a traditional decision letter with three conflicting reviewer opinions and an editor's note saying "please address all comments" knows how maddening that can be. The Frontiers model structurally incentivizes coherent feedback.

In practice, it depends heavily on who your review editor is. Some are actively engaged, synthesizing feedback and mediating between reviewers. Others are essentially passive, forwarding reports without much curation. You can't control which kind you get, but knowing the system exists means you can engage with it. If you receive contradictory reviewer feedback, it's entirely appropriate to write to the review editor asking for clarification on which requests are required versus optional. That's what the system is designed for.

The other distinctive feature: reviewer names are published alongside your paper upon acceptance. This creates real accountability. Reviewers tend to be more constructive when their names are attached. You're less likely to get a one-paragraph dismissal or a demand for two years of additional experiments. The trade-off is that some established researchers won't review for Frontiers because of this transparency, which can skew the reviewer pool toward earlier-career scientists.

Frontiers' editorial philosophy is that if the science is sound, it deserves publication regardless of whether the finding will generate hundreds of citations. This isn't marketing. It's a genuine editorial commitment that changes what reviewers are supposed to evaluate.

What reviewers should be checking:

• Are the methods appropriate and described in reproducible detail?
• Are controls adequate for the experimental system?
• Do statistical analyses match the data structure?
• Are conclusions supported by the evidence presented?
• Is the data presented clearly and completely?

What reviewers shouldn't be evaluating:

• Is this finding "exciting" or "novel"?
• Will this generate a lot of citations?
• Does this represent a major conceptual advance?

This matters most for certain paper types. Descriptive microbiome surveys, environmental isolate characterizations, antimicrobial susceptibility testing of clinical collections, validation studies for detection methods, these all have a realistic path at Frontiers in Microbiology. They'd likely get desk-rejected at mBio or Nature Microbiology, not because the science is weak, but because those journals filter for novelty.

That said, 45-50% of submissions still don't make it. The validity bar is real. If your experimental design has holes, if your 16S amplicon analysis uses outdated pipelines without justification, if your conclusions claim causation from correlative data, you'll get rejected.

Understanding what gets papers rejected here is more useful than understanding what gets them accepted.

Microbiome studies without adequate sample sizes or metadata. This is the most common failure mode I've encountered in microbiology submissions. You've profiled gut microbiomes from 10 patients and 8 controls, run a PCoA, found a separation, and declared a disease-associated signature. Reviewers won't buy it. Without power calculations, without detailed metadata on confounders (diet, medications, BMI, age), and without some form of validation, small-cohort microbiome studies get torn apart. If your sample size is genuinely limited, frame the work as exploratory and don't overclaim.

Environmental microbiology without environmental context. You've isolated a novel bacterium from a hot spring and characterized its genome. Great. But if you haven't connected that genomic analysis to the organism's ecology, why these genes matter in that environment, what metabolic strategies they enable, how this organism fits into the community, the paper reads like a genome announcement with extra steps. Reviewers in Aquatic Microbiology and Systems Microbiology expect ecological interpretation, not just genomic description.

Antimicrobial resistance papers that stop at detection. "We found carbapenem-resistant Klebsiella in hospital wastewater" isn't a story anymore. Ten years ago it was. Now, reviewers want to know: What resistance mechanisms? What mobile genetic elements? What's the transmission risk? What's the clinical context? Detection-only AMR papers without mechanistic or epidemiological depth are increasingly getting rejected, even at journals with Frontiers' acceptance rate.

Review articles that read like annotated bibliographies. Frontiers publishes many reviews, and the section editors are drowning in submissions that summarize 200 papers without taking a position. "Study A found X, Study B found Y" repeated for 8,000 words isn't a review. It's a reference list in paragraph form. Take a stance. Argue for a model. Identify what the field is getting wrong and why.

Running your draft through a pre-submission review before submitting can catch overstatement of conclusions, gaps in statistical reporting, and methodological omissions that trigger these rejection patterns.

Microbiology researchers typically weigh Frontiers in Microbiology against Applied and Environmental Microbiology, mBio, Microbiology Spectrum, and the FEMS journals. Here's how they compare.

The comparison isn't really about quality rankings. It's about what each journal selects for.

mBio wants papers that advance understanding of microbial biology in a way the broad microbiology community cares about. If you've discovered a new regulatory mechanism, elucidated a host-pathogen interaction, or challenged a long-standing model, that's mBio territory. The paper needs broad significance, not just solid execution.

Applied and Environmental Microbiology occupies a sweet spot between applied relevance and mechanistic depth. AEM editors want to see that your environmental or applied microbiology finding is grounded in careful experimental work. The journal has a strong identity around environmental microbiology, biotechnology, and food microbiology, and it's pickier than its IF might suggest.

Microbiology Spectrum, also from ASM, is the closest direct competitor to Frontiers in Microbiology. It has a similar acceptance rate, similar scope, and a similar "validity over novelty" philosophy. The main differences are the review model (traditional at Spectrum, collaborative at Frontiers) and the APC. If you're choosing between these two, it often comes down to whether you want the Frontiers open-review model or ASM's traditional process.

FEMS journals (FEMS Microbiology Ecology, FEMS Microbiology Letters, FEMS Microbes) are society journals with strong reputations in specific subfields. If your work is squarely in microbial ecology, FEMS Microbiology Ecology may be a better fit than the Frontiers generalist umbrella. But they're hybrid rather than fully OA, which matters if your funder requires open access.

The honest strategic calculation: if you've got a finding with broad mechanistic implications, try mBio first. If you've got strong applied or environmental work with careful methodology, AEM is worth the attempt. If you've got solid, well-executed research that doesn't need to rewrite the textbook to be valuable, Frontiers in Microbiology and Microbiology Spectrum are both legitimate choices. Publishing in either isn't settling. It's matching your paper to a journal whose criteria align with what you're actually offering.

Your work is methodologically sound but won't top the news cycle. You've characterized antimicrobial resistance patterns in a regional clinical collection, or you've profiled soil microbial communities across a gradient. The work is clean, the data is interesting, but it's not going to make the journal cover. Frontiers will evaluate it on execution and validity.

You need predictable timelines. With 70-90 days to decision and a collaborative model that reduces contradictory revision demands, Frontiers offers reasonable predictability. If you're a postdoc who needs published papers rather than papers "under review" at journals that might sit on them for six months, the timeline matters.

Your work spans microbiology subdisciplines. A paper on phage therapy for drug-resistant infections touches virology, antimicrobial resistance, and clinical microbiology. At a specialized journal, you'd need to pick one angle. Frontiers' section system lets you find the best-fit section while keeping the interdisciplinary framing intact.

You're publishing a methods paper or descriptive study. Frontiers treats these as legitimate contributions. New culture methods, improved detection assays, large-scale environmental surveys, these all have homes here. Many higher-IF microbiology journals won't consider them unless they're paired with a mechanistic finding.